iBio develops and offers product applications of its iBioLaunch and iBioModulator platforms. It provides collaborators full support for turnkey implementation of its technology for both proprietary and biosimilar products. In addition, the company is developing select product candidates that have been derived from the iBioLaunch platform.
The company today announced the achievement of a critical technology transfer milestone verified by an independent third party laboratory. The validation milestone showed proof that an independent party, without any guidance or assistance from iBio, could use the iBioLaunch system to reliably produce commercial yields of targeted biopharmaceuticals.
iBio’s business commitments to its licensees, however, does include assisting them in effectively implementing proper procedures for the use of its iBio proprietary technology. iBio also provides its licensees quality assurance and quality control documentation and procedures for product and site specific implementation. If necessary, the company will also provide staff training.
On the licensing front, iBio has made good progress so far in 2013. On February 19, it announced the grant of a license for the use of its iBioLaunch platform for development and production of a licensee’s proprietary therapeutic product. On April 9, the company announced another licensee’s commitment for development of a multi-product commercial facility based on its iBioLaunch platform.
For more information about iBio and its proprietary technology platforms, please visit www.ibioinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
